Inactive Instrument

Other languages Q BioMed Inc. Other OTC

Equities

QBIO

US74736N1054

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Q BioMed Inc. Provides Update to Shareholders	23-06-23
Q BioMed Inc. Reports Earnings Results for the First Quarter Ended February 28, 2023	23-06-16
Q BioMed Inc. Reports Earnings Results for the Full Year Ended November 30, 2022	23-05-26
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Patent from United States Patent Office and Notice of Allowance for Europe	23-04-17
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Patent from United States Patent Office and Notice of Allowance for Europe	23-04-14
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent from United States Patent Office	23-02-13
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent from United States Patent Office	23-02-10
Q BioMed Inc.'s Chemotherapeutic Uttroside B Receives Notice of Allowance for Patent from United States Patent Office	23-02-10
Q BIOMED INC. : Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	22-11-18
Q BIOMED INC. Management's Discussion and Analysis of Financial Condition and Results of Operation (form 10-Q)	22-11-03
Q BioMed Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2022	22-11-03
Q BIOMED PROVIDES SHAREHOLDER UPDATE	22-10-11
Q BIOMED ANNOUNCES ISSUANCE OF PATENT FOR GROUNDBREAKING GDF15 BIOMARKER	22-09-27
Q BioMed Inc. Announces Issuance of Patent for Groundbreaking Gdf15 Biomarker	22-09-27
Q BioMed Inc. Provides Update to Shareholders	22-07-29
Q BioMed Inc. Reports Second Quarter Revenues in 2022	22-07-29
Q BioMed : Quarterly Report for Quarter Ending May 31, 2022 (Form 10-Q)	22-07-28
Q BIOMED INC. Management's Discussion and Analysis of Financial Condition and Results of Operation (form 10-Q)	22-07-28
Q BioMed Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2022	22-07-28
Q BioMed announces publication of pre-clinical research showing superior safety and efficacy against current first line therapy of its drug candidate Uttroside-B for liver cancer	22-07-26

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Q BioMed Inc. Other OTC

Equities

QBIO

US74736N1054

Other languages

Filters